The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Accessibility Testing in Government Websites: Challenges and Solutions
Content 1. The Current State of Accessibility in Government Websites 2. Challenges in Implementing Accessibility Testing 3. Why…
Integrating RPA and AI for Intelligent Process Automation
Intelligent Process Automation (IPA): Combining RPA and AI Why Combine RPA and AI? Intelligent Process Automation Use Cases…
Seeq Announces Appointment of Chilton to Board of Directors
Seeq announced the appointment of Anton Chilton to the Seeq Board of Directors, effective immediately.
